Esri and IBM Team Up to Take on Climate Change with Call for Code
11.5.2021 20:23:00 EEST | Business Wire | Press release
Esri, the global leader in location intelligence, today announced it is joining the fourth annual Call for Code Global Challenge. Created by David Clark Cause and launched in partnership with IBM, United Nations Human Rights, and the Linux Foundation, Call for Code is designed to make an immediate and lasting global impact on humanitarian issues, using open-source-powered technology. In this year’s competition, software developers and innovators around the world will take on climate change with open-source software, including Red Hat OpenShift, IBM Cloud, IBM Watson, IBM Blockchain, and data from The Weather Company.
Since Call for Code was launched in 2018, more than 400,000 developers and problem solvers across 179 nations have participated, creating more than 15,000 applications. This year’s competition focuses on three sub-themes related to combating climate change: water availability and consumption, food production and delivery, and economic production and consumption.
The winning team will receive $200,000 and support from the IBM Service Corps, technical experts, and partners—to develop their technology, make their code available for anyone to use in open-source, and deploy their solution on the ground in communities around the world.
For its role in the Call for Code Global Challenge, Esri has made its geospatial analytics software and resources available to each participant, including the following:
- A free ArcGIS Platform developer account.
- A $100 voucher applied to the participant’s ArcGIS account, allowing them to kick-start their solution with cloud hosting, analytical processing, and location services (This is available to the first 100 participants.)
- Access to dedicated community support where participants can connect with mentors that can help them accelerate app development.
"Esri has just released a location platform as a service product that makes it easy for software developers to access geospatial technology," said David Cardella, Product Manager—Developer Technologies, Esri. "Some of the most exciting ways users are putting our software to work is in creating apps that help meet challenges related to climate change. We are excited to introduce our flexible, scalable location services that make content and capabilities available to developers who are building the next generation of geospatial solutions."
For more information and to learn how to get started on the Call for Code Global Challenge with Esri’s offer, visit the ArcGIS Blog. Watch Kareem Yusuf, General Manager, AI Applications and Blockchain, IBM and Jack Dangermond, Founder and President, Esri, discuss their partnership and the importance of technology to address climate change here.
“We are excited to work with Esri and our global ecosystem throughout the 2021 Call for Code Global Challenge to drive, incubate, and deploy solutions that will combat climate change,” said Willie M. Tejada, IBM Chief Developer Advocate and General Manager ISV/Build Ecosystem. “Climate change is a monumental challenge and demands the participation of world-renowned humanitarian experts, business leaders, and technology partners like Esri to have an immediate and lasting effect.”
What makes Call for Code unique is the impact it is making on the ground through deployments in communities around the world. Last year’s winning solution, Agrolly, was designed to support small farmers by providing climate and crop predictions and recommendations. The agriculture industry is one of the most vulnerable to climate change due to its dependence on rainfall and temperature. Since October, the Agrolly team has expanded the solution to new markets and provided hands-on training to more than 500 rural farmers in Mongolia, India, and Brazil, who are testing and using the app to fight the effects of climate change.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
About Call for Code Global Challenge
Developers have revolutionized the way people live and interact with virtually everyone and everything. Where most people see challenges, developers see possibilities. That's why David Clark, the CEO of David Clark Cause, created Call for Code in 2018, and launched it alongside Founding Partner IBM and Charitable Partner UN Human rights. Since then, Call for Code has scaled to include an annual University Challenge in addition to regional prizes and the creation of Call for Code for Racial Justice. This multi-year global initiative is a rallying cry to developers to use their mastery of the latest technologies to drive positive and long-lasting change across the world through code. Call for Code Global Challenge winning solutions are further developed, incubated, and deployed as sustainable open source projects to ensure they can drive positive change. To learn more about past winners and their progress, visit IBM Developer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511006031/en/
Contact information
Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email: jpruchniewski@esri.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom